To study the effects of cholesterol lowering drugs (Atorvastatin and Rosuvastatin) on blood glucose levels.
Not Applicable
- Conditions
- Health Condition 1: null- Stable
- Registration Number
- CTRI/2018/05/013991
- Lead Sponsor
- Jawaharlal Nehru Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
non diabetic, dyslipidemic patients with definite indication for starting hypolipidemic drugs
Exclusion Criteria
known case of diabetes mellitus, heart failure, hepatic ds, renal ds, pregnancy, psychotic ds, malignancy, septicemia, known case of HIV, HBV, HCV and immunocompromised patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fasting glucose levels, post prandial glucose levels, HbA1cTimepoint: 0, 12, 24 weeks
- Secondary Outcome Measures
Name Time Method Conversion to diabetesTimepoint: 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link Atorvastatin and Rosuvastatin to glycemic parameter modulation in dyslipidemic patients?
How does Rosuvastatin compare to Atorvastatin in improving HbA1c and insulin resistance in dyslipidemic individuals?
Which biomarkers correlate with differential glucose-lowering responses to Atorvastatin vs. Rosuvastatin in metabolic syndrome patients?
What are the risks of statin-induced myopathy or new-onset diabetes in CTRI/2018/05/013991's dyslipidemic population?
How do Atorvastatin and Rosuvastatin synergize with GLP-1 agonists in managing cardiometabolic comorbidities?